AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Revance to Participate in the Needham Healthcare Conference

April 2, 2019

NEWARK, Calif.--(BUSINESS WIRE)--Apr 2, 2019--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York, NY.

Chief Financial Officer, Tobin Schilke, is scheduled to present on Tuesday, April 9 at 12:00pm ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary peptide excipient technology to create novel, differentiated therapies. The company’s lead compound, DaxibotulinumtoxinA for Injection (DAXI), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. DAXI has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190402005165/en/

CONTACT: INVESTORS

Revance Therapeutics, Inc.:

Jeanie Herbert, 714-325-3584

jherbert@revance.com

or

Burns McClellan, Inc.:

John Grimaldi, 212-213-0006

jgrimaldi@burnsmc.com

MEDIA

Nadine Tosk, 504-453-8344

nadinepr@gmail.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENERAL HEALTH

SOURCE: Revance Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 04/02/2019 04:05 PM/DISC: 04/02/2019 04:05 PM

http://www.businesswire.com/news/home/20190402005165/en